Oligomerix to Present at Alzheimer's Association International Conference
Oligomerix plans to complete preclinical testing of OLX-07010 by year end and begin Phase 1 clinical trials by 2Q22.
- Oligomerix plans to complete preclinical testing of OLX-07010 by year end and begin Phase 1 clinical trials by 2Q22.
- Oligomerix is headquartered at the Westchester Park Center in White Plains, New York and has lab facilities at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.
- Oligomerix is seeking strategic partners to support the acceleration and advancement of these important programs.
- For more information about Oligomerix, please visit our new website at https://oligomerix.com/ .